Increased 5-hydroxymethylcytosine is a favorable prognostic factor of Helicobacter pylori-negative gastric cancer patients

Figure 1 Flow chart of the subjects enrolled. GC: Gastric cancer; H. pylori: Helicobacter pylori.

Figure 2 5-hydroxymethylcytosine level measurement compared between tumor vs control tissues and Helicobacter pylori-negative vs positive subgroups. A: Tumor vs control tissues; B: Helicobacter pylori -negative vs positive subgroups. 5-hmC: 5-hydroxymethylcytosine.

Figure 3 Kaplan–Meier estimates of overall survival in gastric cancer patients. A: Total gastric cancer (GC) patients; B: GC patients with negative Helicobacter pylori (H. pylori) infection; C: GC patients with positive H. pylori infection; D: GC patients with Ⅰ or Ⅱ TNM stage; E: GC patients with Ⅲ TNM stage. 5-hmC: 5-hydroxymethylation.